CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding CytomX Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 122 | 1 | 114 | −7 |
| Shares | 56.7M | 50.8K | 54.0M | −2.65M (−4.7%) |
| Value | $358.9M | $322.0K | $274.8M | −$83.7M (−23.4%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held CytomX Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Soleus Capital Management, L.P. | 261,050 | $1.33M | 0.21% |
| Gsa Capital Partners LLP | 249,146 | $1.27M | 0.13% |
| AXA S.A. | 231,600 | $1.18M | 0.00% |
| HRT Financial LP | 149,176 | $759.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 54,945 | $280.0K | 0.00% |
| Franklin Resources Inc | 50,800 | $259.0K | 0.00% |
| Jump Financial, LLC | 17,300 | $88.0K | 0.01% |
| WestHill Financial Advisors, Inc. | 17,082 | $87.0K | 0.03% |
| Forefront Analytics, LLC | 13,394 | $68.0K | 0.02% |
| IFP Advisors, Inc | 222 | $1.00K | 0.00% |
Sold out (17)
Institutions that held CytomX Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Perceptive Advisors LLC | 1,640,957 | $10.4M |
| Citadel Advisors LLC | 769,766 | $4.87M |
| Bank of Montreal | 195,157 | $1.27M |
| Jane Street Group, LLC | 84,724 | $536.0K |
| SEI Investments Co | 64,469 | $399.0K |
| Engineers Gate Manager LP | 55,035 | $348.0K |
| Susquehanna Fundamental Investments, LLC | 39,463 | $250.0K |
| Raymond James Financial Services Advisors, Inc. | 22,840 | $145.0K |
| XTX Topco Ltd | 21,422 | $136.0K |
| Qube Research & Technologies Ltd | 18,101 | $115.0K |
| Boothbay Fund Management, LLC | 15,182 | $96.0K |
| Thrivent Financial for Lutherans | 13,175 | $83.0K |
| Diversified Trust Co | 10,582 | $67.0K |
| Balyasny Asset Management LLC | 10,059 | $64.0K |
| Group One Trading, L.P. | 1,800 | $11.0K |
| Advisory Services Network, LLC | 412 | $3.00K |
| Meeder Asset Management Inc | 92 | $1.00K |
Not filed for Q3 2021 yet (1)
Institutions that held CytomX Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| QS Investors, LLC | 50,800 | $322.0K |